MACRILEN Drug Patent Profile
✉ Email this page to a colleague
When do Macrilen patents expire, and when can generic versions of Macrilen launch?
Macrilen is a drug marketed by Novo and is included in one NDA. There is one patent protecting this drug.
This drug has eleven patent family members in ten countries.
The generic ingredient in MACRILEN is macimorelin acetate. Two suppliers are listed for this compound. Additional details are available on the macimorelin acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Macrilen
Macrilen was eligible for patent challenges on December 20, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 20, 2024. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for MACRILEN
International Patents: | 11 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Clinical Trials: | 2 |
Patent Applications: | 40 |
Drug Prices: | Drug price information for MACRILEN |
What excipients (inactive ingredients) are in MACRILEN? | MACRILEN excipients list |
DailyMed Link: | MACRILEN at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for MACRILEN
Generic Entry Date for MACRILEN*:
Constraining patent/regulatory exclusivity:
FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD) NDA:
Dosage:
FOR SOLUTION;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MACRILEN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
VA Office of Research and Development | Phase 3 |
Novo Nordisk A/S | Phase 3 |
AEterna Zentaris | Phase 3 |
Pharmacology for MACRILEN
Drug Class | Growth Hormone Secretagogue Receptor Agonist |
Mechanism of Action | Growth Hormone Secretagogue Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for MACRILEN
US Patents and Regulatory Information for MACRILEN
MACRILEN is protected by one US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of MACRILEN is ⤷ Try a Trial.
This potential generic entry date is based on FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD).
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting MACRILEN
Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN
FDA Regulatory Exclusivity protecting MACRILEN
FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo | MACRILEN | macimorelin acetate | FOR SOLUTION;ORAL | 205598-001 | Dec 20, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novo | MACRILEN | macimorelin acetate | FOR SOLUTION;ORAL | 205598-001 | Dec 20, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MACRILEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novo | MACRILEN | macimorelin acetate | FOR SOLUTION;ORAL | 205598-001 | Dec 20, 2017 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MACRILEN
See the table below for patents covering MACRILEN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Portugal | 1984744 | ⤷ Try a Trial | |
Hungary | 0302026 | ⤷ Try a Trial | |
Slovakia | 17562002 | Zlúčeniny zvyšujúce sekréciu rastového hormónu, farmaceutický prostriedok s ich obsahom a ich použitie (Growth hormone secretagogues) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MACRILEN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1289951 | 300999 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: MACIMORELIN; REGISTRATION NO/DATE: EU/1/18/1337 20190115 |
1289951 | CA 2019 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MACIMORELIN, EN FARMACEUTISK SAMMENSAETNING DERAF ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1337 20190115 |
1289951 | 132019000000099 | Italy | ⤷ Try a Trial | PRODUCT NAME: MACIMORELINA, OPZIONALMENTE NELLA FORMA DI UNA COMPOSIZIONE FARMACEUTICA, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE, COMPRESA MACIMORELINA ACETATO(MACIMORELIN AETERNA ZENTARIS - MACIMORELINA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1337, 20190115 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |